# EDGAR Filing Document

**Accession Number:** 0001650664
**File Stem:** 0001650664-25-000148
**Filing Date:** 2025-10
**Character Count:** 11164
**Document Hash:** eb930bf2564357d4ec6930788ce41359
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001650664-25-000148.hdr.sgml**: 20251009

**ACCESSION NUMBER**: 0001650664-25-000148

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251009

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251009

**DATE AS OF CHANGE**: 20251009

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Editas Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001650664
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464097528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37687
- **FILM NUMBER:** 251385443

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-401-9000

**MAIL ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

?xml version='1.0' encoding='ASCII'? edit-20251009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________________________________________________

**FORM 8-K**

_________________________________________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 9, 2025

_________________________________________________________________________________________

**Editas Medicine, Inc.**

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37687** | **46-4097528** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | | |
|:---|:---|:---|
| **11 Hurley Street** | **11 Hurley Street** | |
| **Cambridge,** | **Massachusetts** | **02141** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | EDIT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On October 9, 2025, Editas Medicine, Inc. (the "Company") issued a press release titled "Editas Medicine Reports *In Vivo* Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress," a copy of which is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On October 9, 2025, at the 32nd Annual European Society of Gene and Cell Therapy Congress, the Company reported *in vivo* preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol ("LDL-C") through upregulation of the LDL receptor ("LDLR").

In preclinical studies in non-human primates, EDIT-401 achieved LDL-C reductions in non-human primates equal to or exceeding 90% within 48 hours of a single dose. EDIT-401 also achieved LDL-C reductions equal to or exceeding 90% in mice with high baseline LDL-C and reduced LDLR function. LDL-C reductions were maintained in mouse models in a three-month study.

The Company's EDIT-401 therapeutic strategy includes the use of a CRISPR/Cas9 nuclease and dual guide RNAs with lipid nanoparticle delivery to disrupt negative regulatory elements in the 3' UTR, increasing mRNA stability enabling potent LDLR upregulation. The Company observed that the LDL-C reductions following EDIT-401 treatment were achieved with an at least six-fold mean increase in LDLR protein in the non-human primate liver, requiring only a moderate level of functional editing of *LDLR* alleles.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press release issued by the Company on October 9, 2025\*](esgct_datareleasexfinal.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\*This exhibit shall be deemed to be furnished and not filed.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | EDITAS MEDICINE, INC. | EDITAS MEDICINE, INC. |
| Date: October 9, 2025 | By: | /s/ Amy Parison |
|  |  | Amy Parison |
|  |  | Chief Financial Officer |

---

## Ex-99

![image_0.jpg](image_0.jpg)

**<br>Editas Medicine Reports *In Vivo* Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32**<sup>nd</sup> **Annual Congress**

*Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models*

**CAMBRIDGE, Mass., October 9, 2025** – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported *in vivo* preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol (LDL-C), at the 32<sup>nd</sup> Annual European Society of Gene and Cell Therapy **(**ESGCT) Congress in Seville, Spain. The Company shared results from preclinical studies demonstrating potent and durable reductions in LDL-C through upregulation of the LDL receptor (LDLR).

**Key EDIT-401 Data Presented includes**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Robust efficacy data:** ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Optimized therapeutic strategy:**

oCRISPR/Cas9 nuclease and dual gRNAs with LNP delivery disrupt negative regulatory elements in the 3' UTR, increasing mRNA stability enabling potent LDLR upregulation

o ≥6-fold mean increase in LDLR protein in the NHP liver, requiring only a moderate level of functional editing of *LDLR* alleles

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Durable effect:** LDL-C reduction maintained in mouse models in a three-month study

"The *in vivo* proof-of-concept data presented today reinforce the potential impact of our differentiated upregulation strategy. In preclinical non-human primate studies, EDIT-401 achieved robust efficacy data with a ≥90% mean LDL-C reduction. These data strengthen our conviction that EDIT-401 represents a novel therapeutic approach with the potential to significantly improve outcomes for people living with high LDL cholesterol," said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.

Abstracts are available to registrants on the <u>ESGCT website</u>. The presentation will also be posted to the "<u>Posters & Presentations</u>" section of the Company's website at the time of the presentation and will remain accessible following the event.<br>

**Oral Presentation Details:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Title:** A transformative LDL cholesterol-lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Session Date and Time:** Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET

------

![image_0.jpg](image_0.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Session Title:** 9A: Gene Editing II, Ex Vivo Applications

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Room:** Parallel A

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Presenter:** Linda Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Final Abstract Number:** OR069

**About Editas Medicine** 

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative *in vivo* medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision *in vivo* gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

###

**Investor and Media Contacts:** 

<u>ir@editasmed.com</u> 

<u>media@editasmed.com</u> 

<br>